The FDA granted 510(k) clearance to two devices, HyHub and HyHub Duo, that act as docking stations for dual vial units to ...

Analysts are estimating that Takeda Pharmaceutical will report an earnings per share (EPS) of $0.47. The market awaits Takeda Pharmaceutical's announcement, with hopes high for news of surpassing ...

NET PROFIT FORECAST: Takeda's net profit is expected to have declined 0.4% from a year earlier to 94.89 billion yen, equivalent to $642.6 million, for the three months ended June 30, according to a ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals. Read why TAK stock is a hold.

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential ...

While Takeda is not “laser focused” on one mechanism, Warren said the company is “very interested” in checkpoint inhibitors and CAR-T therapies.

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

Takeda's inflammatory bowel disease drug vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has been recommended for US regulatory approval for use in adults with moderately to ...